Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza) for the Treatment of Children and Adults with X–Linked Hypophosphatemia (XLH)

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing